These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 34585213)
1. Commentary: The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice. Gauthier S; Rosa-Neto P J Prev Alzheimers Dis; 2021; 8(4):411. PubMed ID: 34585213 [No Abstract] [Full Text] [Related]
5. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220 [TBL] [Abstract][Full Text] [Related]
6. Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research. Doody R J Prev Alzheimers Dis; 2021; 8(4):393-395. PubMed ID: 34585210 [No Abstract] [Full Text] [Related]
7. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Gerding H; Monés J; Tadayoni R; Boscia F; Pearce I; Priglinger S Br J Ophthalmol; 2015 Mar; 99(3):297-304. PubMed ID: 25075121 [TBL] [Abstract][Full Text] [Related]
9. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491 [TBL] [Abstract][Full Text] [Related]
10. Off-label use of aducanumab for cerebral amyloid angiopathy. Greenberg SM; Cordonnier C; Schneider JA; Smith EE; van Buchem MA; van Veluw SJ; Verbeek MM; Viswanathan A; Werring DJ Lancet Neurol; 2021 Aug; 20(8):596-597. PubMed ID: 34237272 [No Abstract] [Full Text] [Related]
15. From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. Frost CV; Zacharias M Proteins; 2020 Dec; 88(12):1592-1606. PubMed ID: 32666627 [TBL] [Abstract][Full Text] [Related]
16. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers? Piazza F; Winblad B J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492 [TBL] [Abstract][Full Text] [Related]
17. Revisiting FDA Approval of Aducanumab. Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282 [No Abstract] [Full Text] [Related]
18. Standard-of-care testimony: best practices or reasonable care? Simon RI J Am Acad Psychiatry Law; 2005; 33(1):8-11. PubMed ID: 15809234 [No Abstract] [Full Text] [Related]
19. A contentious FDA ruling for Alzheimer's disease. The Lancet Neurology Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273 [No Abstract] [Full Text] [Related]
20. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source. Patel KR Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718 [No Abstract] [Full Text] [Related] [Next] [New Search]